Apples will never be oranges, but when you go fishing you may get a bite

Dronedarone is the newest available oral antiarrhythmic drug (AAD). In a paper by Ehrlich et al. [1] accompanying this editorial the authors report on risks for myocardial infarction (MI) and stroke in AF patients given a first prescription for dronedarone, amiodarone, flecainide, propafenone, or sotalol in 1258 general and 62 cardiology practices between January 2010 and March 2017. They attempt to compare MI and stroke risks in dronedarone patients (n  = 3498) versus those treated with all the other stated antiarrhythmic drugs (AAD) analyzed in combination (n = 17,724).
Source: International Journal of Cardiology - Category: Cardiology Authors: Tags: Editorial Source Type: research